Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind's psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: ...
The blood-brain barrier (BBB) prevents the passage of foreign substances from the blood to the brain's extracellular fluid. Several drugs that permeate through the BBB are compromised, and only an ...
Intranasal Drug and Vaccine Delivery Market, By Product Type (Nasal Drops and Nasal Sprays), By Application (Vaccination, Pain Management, Respiratory Disorders, and Others), By End-user (Hospitals, ...
Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the filing of a divisional patent application for its Trap & Target (T&T) platform technology with the Israel Patent Office.
(MENAFN- EIN Presswire) EINPresswire/ -- Overview of the Market: The Global Intranasal Drug Delivery Market has emerged as one of the fastest-growing therapeutic administration segments, led by rising ...
Clearmind Medicine (CMND) has signed a non-binding Letter of Intent with Polyrizon (PLRZ) to develop a novel intranasal formulation for its psychedelic-based treatment applications. The collaboration ...
Hosted on MSN
New study validates insulin nasal spray to deliver Alzheimer's drug directly to the brain
A groundbreaking brain imaging study from Wake Forest University School of Medicine confirms a vital step toward new Alzheimer's disease treatments: Intranasal insulin, delivered via a simple nasal ...
Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results